Hypertension in kidney transplant recipients

Transplant International

Volumn 24, Issue 6, 2011, Pages 523-533

  Ponticelli, Claudio ^a   Cucchiari, David ^a   Graziani, Giorgio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

hypertension; immunosuppressive therapy; kidney transplantation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; NATRIURETIC PEPTIDE RECEPTOR A;

AGE DETERMINATION; ANEMIA; ARTERIOVENOUS FISTULA; BIOPSY TECHNIQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GASTROESOPHAGEAL REFLUX; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEREDITARY HYPERTENSION; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; KIDNEY ALLOGRAFT; KIDNEY ARTERY STENOSIS; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIFESTYLE; NEPHRECTOMY; NONHUMAN; OLIGOANURIA; OLIGURIA; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM EXCRETION; VASCULAR RESISTANCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCINEURIN; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CYCLOSPORINE; DIURETICS; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIFE STYLE; RENAL ARTERY OBSTRUCTION; VASCULAR RESISTANCE;

EID: 79955556863     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01242.x     Document Type: Review

References (123)

1. Miller LW,. Cardiovascular toxicity of immunosuppressive agents. Am J Transplant 2002; 2: 807.
2. Midvtvedt K, Hartmann A,. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002; 17: 1166.
3. Schwenger V, Zeier M, Ritz E,. Hypertension after renal transplantation. Ann Transplant 2001; 6: 25.
4. Castillo-Lugo JA, Vergne-Marini P,. Hypertension in kidney transplantation. Semin Nephrol 2005; 4: 252.
5. Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol 2007; 18: 1607.
6. Kurtz A, Della Bruna R, Kühn K,. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988; 33: 947.
7. Bartholomeusz B, Hardy KJ, Nelso AS, Philips PA,. Modulation of nitric oxide improves cyclosporine A-induced hypertension in rats and primates. J Hum Hypertens 1998; 12: 839.
8. Koomans HA, Ligtenberg G,. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001; 72 (Suppl. 6): S9.
9. Morales JM, Andres A, Rengel M, Rodicio JL,. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 121.
10. Olyaei AJ, De Mattos AM, Bennett WM,. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
11. Klein IH, Abrahams AC, van Ede T, Oey PL, Ligtenberg G, Blankestijn PJ,. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity. J Hypertens 2010; 28: 1928.
12. Matsuo S, Lopez-Guisa JM, Cai X, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005; 67: 2221.
13. Dai C, Yang J, Liu Y,. Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 2003; 278: 12537.
14. Hill CS,. Turning off Smads: identification of a Smad phosphatase. Dev Cell 2006; 10: 412.
15. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME,. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J 2006; 393: 60160.
16. Chen HB, Shen J, Ip YT, Xu L,. Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev 2006; 20: 648.
17. Sharma VK, Bologa RM, Xu GP, et al. Intragraft TGFβ1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297.
18. Liu T, Feng XH,. Regulation of TGF-beta signalling by protein phosphatases. Biochem J 2010; 430: 191.
19. Paul LC,. Chronic allograft nephropathy. Kidney Int 1999; 56: 783.
20. Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS,. The sodium retaining effects of cyclosporine. Kidney Int 1992; 41: 1599.
21. Curtis JJ,. Posttransplant hypertension. Transplant Proc 1998; 30: 2009.
22. Bechstein WO,. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13: 313.
23. Klein IH, Abrahams A, van Ede T, Hené RJ, Koomans HA, Ligtenberg G,. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732.
24. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J,. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775.
25. Krämer BK, Del Castillo D, Margreiter R,. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant 2008; 23: 2386.
26. Koomans HA, Ligtenberg G,. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001; 72 (6 Suppl.): S9.
27. Russ G, Segoloni G, Oberbauer R, et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80: 1204.
28. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
29. Ponticelli C, Montagnino G, Aroldi A,. Hypertension after transplantation. Am J Kidney Dis 1993; 21 (Suppl. 2): S73.
30. Ratcliffe PJ, Dudley CRK, Higgins RM, et al. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643.
31. Zhang J, Geller DS,. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol 2008; 19: 1291.
32. Knight SR, Morris PJ,. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
33. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001; 59: 1158.
34. Wadei HM, Textor SC,. Hypertension in the kidney transplant recipient. Transplant Rev 2010; 24: 105.
35. Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P,. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; 2: 739.
36. Guidi E, Menghetti D, Milani S, et al. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidney coming from donors with or without hypertension in their families. J Am Soc Nephrol 1996; 7: 1131.
37. Ducloux D, Motte G, Kribs M, et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002; 57: 409.
38. Robertson JI, Morton JJ, Tillman DM, Lever AF,. The pathophysiology of renovascular hypertension. J Hypertens Suppl 1986; 4: S95.
39. Audard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant 2006; 6: 95.
40. De Morais RH, Muglia VF, Mamere AE, et al. Duplex Doppler sonography of transplant renal artery stenosis. J Clin Ultrasound 2003; 31: 135.
41. Kutkuhn B, Hollenbeck M, Westhoff A, Ivens K, Heering P, Grabensee B,. Renin secretion and captopril stimulation in hypertensive renal transplant recipients. Urol Int 1994; 52: 82.
42. Mousa D, Hamilton D, Hassan A, Al-Sulaiman M, Al-Hawas F, Al-Khader A,. The diagnosis of segmental transplant renal artery stenosis by captopril renography. Clin Nucl Med 1999; 24: 504.
43. Kasiske BL,. Ischemic heart disease after renal transplantation. Kidney Int 2002; 61: 356.
44. Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084.
45. Kendrick E,. Cardiovascular disease and the renal transplant recipient. Am J Kidney Dis 2001; 38 (Suppl. 6): S36.
46. Spence JD,. Stroke prevention in the high-risk patient. Expert Opin Pharmacother 2007; 8: 1851.
47. Ross R,. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115.
48. Mange KC, Cizman B, Joffe M, Feldman HI,. Arterial hypertension and renal allograft survival. JAMA 2000; 283: 633.
49. Shirali AC, Bia MJ,. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3: 491.
50. Opelz G, Wujciak T, Ritz E,. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217.
51. Kasiske BL, Anjum S, Shah R,. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
52. Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209.
53. Vetromile F, Szwarc I, Garrigue V, et al. Early high pulse pressure is associated with graft dysfunction and predicts poor kidney allograft survival. Transplantation 2009; 8: 1088.
54. Staessen JA, Wang JG, Thijs L,. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305.
55. Law MR, Morris JK, Wald NJ,. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
56. Opelz G, Döhler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
57. Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009; 22: 1073.
58. Kasiske B, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299.
59. Mailloux LU, Levey AS,. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl): S120.
60. Kasiske BL, Vasquez HA, Harmon WE, et al. For the American Society of Transplantation; Recommendations for outpatient surveillance of renal transplant recipient. J Am Soc Nephrol 2000; 11 (Suppl): S1.
61. Hackam DG, Khan NA, Hemmelgarn BR,. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2010; 26: 249.
62. Dunn BL, Teusink AC, Taber DJ, Hemstreet BA, Uber LA, Weimert NA,. Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother 2010; 8: 1259.
63. Schweitzer E, Matas AJ, Gillingham KG, et al. Cause of renal allograft loss. Progress in the 1980s, challenges for the 1990s. Ann Surg 1991; 214: 679.
64. Hayden MR, Tyagi SC,. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab 2004; 1: 1.
65. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59: 1276.
66. Holland OB, Gomez-Sanchez CE, Kuhnert LV, Poindexter C, Pak CY,. Antihypertensive comparison of furosemide with hydrochlorothiazide for black patients. Arch Intern Med 1979; 139: 1015.
67. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y,. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349.
68. Rahn KH, Barenbrock M, Frtischka E, et al. Effect of nitrendipine on renal function in renal transplant patients treated with cyclosporine: a randomised trial. Lancet 1999; 354: 1415.
69. Madsen JK, Sørensen SS, Hansen HE, Pedersen EB,. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 1998; 13: 2327.
70. Rodicio JL,. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35 (3 Suppl. 1): S7.
71. English J, Evan A, Houghton D, Bennett W,. Cyclosporine induces acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135.
72. Cross NB, Webster AC, Masson P, O'connell PJ, Craig JC,. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7.
73. Sharp A, Mayet J,. Regression of left ventricular hypertrophy: hoping for a longer life. J Renin Angiotensin Aldosterone Syst 2002; 3: 141.
74. Demme RA,. Hypertension in the kidney transplant patient. Graft 2001; 4: 248.
75. Furberg CD, Psaty BM, Meyer JV,. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326.
76. Kasiske BL, Chakkera H, Roel J, et al. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
77. Pochet JM, Pirson Y,. Cyclosporine-diltiazem interaction. Lancet 1986; 1: 979.
78. Undholm A, Henricson S,. Verapamil inhibits cyclosporine metabolism. Lancet 1987; 1: 1962.
79. Renton KW,. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985; 34: 2543.
80. Pesavento TE, Jones PA, Julian BA, Curtis JJ,. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients. Results of a prospective study. J Am Soc Nephrol 1996; 7: 831.
81. Toupance O, Lavaud S, Canivet E, Beraaud C, Hotton JM, Chanard J,. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension 1994; 24: 297.
82. Bourbigot B, Guiserix J, Airiau J, BressoUette L, Morin JF, Cledes J,. Nicardipine increases cyclosporine blood levels. Lancet 1986; 1: 1447. (Pubitemid 16122535)
83. Propper DJ, Whiting PH, Power DA, Edward N, Catto GRD,. The effect of nifedipine on graft function in renal allograft recipients treated with cyclosporine A. Clin Nephrol 1989; 32: 62.
84. Copur MS, Tasdemir I, Jurgan C, Yasavul U, Caglar S,. Effects of nitrendipine on blood cyclosporine A level in patients with post transplant hypertension. Nephron 1989; 2: 227.
85. Mourad G, Ribstein J, Mimran A,. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43: 419.
86. Burnier M, Brunner HR,. Angiotensin II receptor antagonists in hypertension. Kidney Int 1998; 54 (Suppl. 68): S10.
87. Holgado R, Anaja F, Del Castillo D,. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 117.
88. Olyaei AJ, de Mattos AM, Benne WM,. A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999; 58: 1011.
89. Curtis JJ, Laskow PA, Jones PA, et al. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993; 3: 1570.
90. Curtis JJ,. Treatment of hypertension in renal allograft patients: does drug selection make a difference? Kidney Int 1997; 63 (Suppl): S75.
91. Formica Jr RN, Friedman AL, Lorber MI, et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006; 21: 1389.
92. Jennings DL, Taber DJ,. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharmacother 2008; 42: 116.
93. Elliott WJ,. Traditional drug therapy of hypertension in transplant recipients. J Hum Hypertens 1998; 12: 845.
94. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145.
95. Stigant CE, Cohen J, Vivera M, Zaltzman JS,. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58.
96. Suwelack B, Gerardt U, Hausberg M, Rahn KH, Hohage H,. Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 2000; 86: 583.
97. Hernandez D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58: 889.
98. Cieciura T, Senatorski G, Rell K, et al. Influence of angiotensin-converting-enzyme inhibitor treatment of the carotid artery intima-media complex in renal allograft recipients. Trasplant Proc 2000; 32: 1335.
99. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE,. Posttransplant erythrocytosis. Kidney Int 2003; 63: 1187.
100. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA,. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350.
101. Heinze G, Collins S, Benedict MA, et al. The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 2006; 82: 1441.
102. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787.
103. Opelz G, Zeier M, Laux G, Morath C, Döhler B,. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257.
104. Danovitch GM,. Can ACE-inhibitors prevent chronic allograft failure? Am J Kidney Dis 2001; 37: 866.
105. Cruzado JM, Rico J, Grinyõ JM,. The renin angiotensin system blockade in kidney transplantation: pros and cons. Transpl Int 2008; 21: 304.
106. Weir MR, Moser M,. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139: 174.
107. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL,. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905.
108. Murad MH, Coto-Yglesias F, Wang AT, et al. Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94: 741.
109. Fonseca VA,. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010; 26: 615.
110. Nash DT,. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol 1990; 13: 764.
111. Freiberger V, Amann K, Heemann U, Frank H,. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int 2009; 22: 1110.
112. Hausberg M, Lang D, Levers A,. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. J Hypertens 2006; 24: 957.
113. Fricke L, Diehn C, Steinhoff J, et al. Treatment of post-transplant hypertension by laparoscopic bilateral nephrectomy. Transplantation 1998; 65: 1182.
114. Lucas SM, Mofunanya TC, Goggins WC, Sundaram CP,. Staged nephrectomy versus bilateral laparoscopic nephrectomy in patients with autosomal dominant polycystic kidney disease. J Urol 2010; 184: 2054.
115. Rao VK,. Post-transplant medical complications. Surg Clin North Am 1998; 78: 113.
116. Benoit G, Moukarzel M, Hiesse C, Verdelli G, Charpentier B, Fries D,. Transplant renal artery stenosis: experience and comparative results between surgery and angioplasty. Transpl Int 1990; 3: 137.
117. Beecroft JR, Rajan DK, Clark TW, Robinette M, Stavropoulos SW,. Transplant renal artery stenosis: outcome after percutaneous intervention. J Vasc Interv Radiol 2004; 15: 1407.
118. Hagen G, Wadström J, Magnusson M, Magnusson A,. Outcome after percutaneous transluminal angioplasty of arterial stenosis in renal transplant patients. Acta Radiol 2009; 50: 270.
119. Henning BF, Kuchlbauer S, Böger CA, et al. Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis. Clin Nephrol 2009; 71: 543.
120. Hurst FP, Abbott KC, Neff RT, et al. Incidence, predictors and outcomes of transplant renal artery stenosis after kidney transplantation: analysis of USRDS. Am J Nephrol 2009; 30: 459.
121. Voiculescu A, Schmitz M, Hollenbeck M, et al. Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients. Am J Transplant 2005; 5: 1731.
122. Jin KB, Hwang EA, Han SY, et al. Delayed presentation of arteriovenous fistula and pseudoaneurysms in a renal transplant patient 10 years after percutaneous allograft biopsy. Transplant Proc 2008; 40: 2444.
123. Mavili E, Dönmez H, Dursun I, Poyrazoǧlu H, Sipahioglu MH, Ozcan N,. Embolization of postbiopsy and postnephrostomy complications in transplanted kidney: a case report. Transplant Proc 2008; 40: 3767.